Periprocedural Complications With Balloon Pulmonary Angioplasty: Analysis of Global Studies
- PMID: 37100561
- DOI: 10.1016/j.jcin.2023.01.361
Periprocedural Complications With Balloon Pulmonary Angioplasty: Analysis of Global Studies
Abstract
Background: Balloon pulmonary angioplasty (BPA) was introduced as a treatment modality for patients with inoperable, medically refractory chronic thromboembolic pulmonary hypertension decades ago; however, reports of high rates of pulmonary vascular injury have led to considerable refinement in procedural technique.
Objectives: The authors sought to better understand the evolution of BPA procedure-related complications over time.
Methods: The authors conducted a systematic review of original articles published by pulmonary hypertension centers globally and performed a pooled cohort analysis of procedure-related outcomes with BPA.
Results: This systematic review identified 26 published articles from 18 countries worldwide from 2013 to 2022. A total of 1,714 patients underwent 7,561 total BPA procedures with an average follow up of 7.3 months. From the first period (2013-2017) to the second period (2018-2022), the cumulative incidence of hemoptysis/vascular injury decreased from 14.1% (474/3,351) to 7.7% (233/3,029) (P < 0.01); lung injury/reperfusion edema decreased from 11.3% (377/3,351) to 1.4% (57/3,943) (P < 0.01); invasive mechanical ventilation decreased from 0.7% (23/3,195) to 0.1% (4/3,062) (P < 0.01); and mortality decreased from 2.0% (13/636) to 0.8% (8/1,071) (P < 0.01).
Conclusions: Procedure-related complications with BPA, including hemoptysis/vascular injury, lung injury/reperfusion edema, mechanical ventilation, and death, were less common in the second period (2018-2022), compared with first period (2013-2017), likely from refinement in patient and lesion selection and procedural technique over time.
Keywords: balloon pulmonary angioplasty; chronic thromboembolic pulmonary hypertension; pulmonary artery angioplasty.
Published by Elsevier Inc.
Conflict of interest statement
Funding Support and Author Disclosures Dr Krasuski has been a consultant to Actelion/Janssen Pharmaceuticals, Bayer Pharmaceuticals, Gore Medical and Medtronic; and has received research funding from the Adult Congenital Heart Association, Actelion, Corvia, CryoLife, Edwards Lifesciences, and Medtronic. Dr Rosenfield has been a consultant to or served on scientific advisory boards for Abbott Vascular, Althea Medical, Angiodynamics, Auxetics, Becton-Dickinson, Boston Scientific, Contego, Crossliner, Innova Vascular, Inspire MD, Janssen/Johnson and Johnson, Magneto, Mayo Clinic, MedAlliance, Neptune Medical, Penumbra, Philips, Surmodics, Terumo, Thrombolex, Truvic, Vasorum, and Vumedi; has received institutional research grants from the NIH, Abiomed, Boston Scientific, Novo Nordisk, Penumbra, and Gettinge-Atrium; has equity interest in Accolade, Access Vascular, Aerami, Althea Medical, Auxetics, Contego, Crossliner, Cruzar Systems, Embolitech, Endospan, Imperative Care/Truvic, Innova Vascular, InspireMD, JanaCare, Magneto, MedAlliance, Neptune Medical, Orchestra, PQ Bypass, Prosomnus, Shockwave, Skydance, Summa Therapeutics, Thrombolex, Valcare, Vasorum, and Vumedi; and is a board member and founder of the National PERT Consortium. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Comment in
-
Time to Standardize Definitions for the Success and Complications of Balloon Pulmonary Angioplasty: A Quality Imperative.JACC Cardiovasc Interv. 2023 Apr 24;16(8):984-985. doi: 10.1016/j.jcin.2023.02.017. Epub 2023 Mar 22. JACC Cardiovasc Interv. 2023. PMID: 36964098 No abstract available.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical